Your browser version may not work well with NCBI's Web applications. More information here...
1: Aliment Pharmacol Ther. 2008 Jun 26. [Epub ahead of print]
Related Articles, Links
Click here to read Click here to read
Clinical trial: protective effect of a commercial fish protein hydrolysate against indomethacin (NSAID)-induced small intestinal injury.

Marchbank T, K Limdi J, Mahmood A, Elia G, J Playford R.

Centre for Gastroenterology, Institute of Cell and Molecular Science, Barts & The London School of Medicine, Queen Mary University of London, London, UK.

Background: A partially hydrolysed and dried product of pacific whiting fish is marketed as a health food supplement supporting 'intestinal health'. We examined whether it influenced the small intestinal damaging side effects of the non-steroidal anti-inflammatory drug, indomethacin. Methods: Eight human volunteers completed a double-blind, placebo-controlled, crossover protocol of clinically relevant dose of indomethacin (50 mg tds po for 5 days) with 7 days of fish hydrolysate or placebo starting 2 days prior to indomethacin. Changes in gut permeability were assessed using 5 h urinary lactulose: rhamnose (L/R) ratios. Results: Fish hydrolysate given alone did not affect permeability. In the main study (N=8), baseline values were similar for both arms (0.28 +/- 0.05 and 0.35 +/- 0.07). Administration of indomethacin (+ placebo) caused a five-fold rise in L/R ratios (increasing to 1.54 +/- 0.35) whereas L/R ratios in the same subjects ingesting indomethacin + fish hydrolysate, was only 0.59 +/- 0.14, (p <0.01 vs. indomethacin alone). Dyspeptic symptoms occurred in 4/8 subjects taking indomethacin alone but 0/8 when hydrolysate was co-administered. Conclusion: Natural bioactive products (nutriceuticals), such as this, may provide a novel approach to the prevention and treatment of NSAID-induced and other gastrointestinal injurious conditions.

PMID: 18616646 [PubMed - as supplied by publisher]